210 related articles for article (PubMed ID: 26935996)
1. Effects of Time to Treatment on Biochemical and Clinical Outcomes for Patients With Prostate Cancer Treated With Definitive Radiation.
Dong Y; Li T; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Clin Genitourin Cancer; 2016 Oct; 14(5):e463-e468. PubMed ID: 26935996
[TBL] [Abstract][Full Text] [Related]
2. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
3. Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy.
Shilkrut M; McLaughlin PW; Merrick GS; Vainshtein JM; Feng FY; Hamstra DA
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):721-8. PubMed ID: 23664325
[TBL] [Abstract][Full Text] [Related]
4. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
5. External beam radiation therapy and a low-dose-rate brachytherapy boost without or with androgen deprivation therapy for prostate cancer.
Strom TJ; Hutchinson SZ; Shrinath K; Cruz AA; Figura NB; Nethers K; Biagioli MC; Fernandez DC; Heysek RV; Wilder RB
Int Braz J Urol; 2014; 40(4):474-83. PubMed ID: 25251952
[TBL] [Abstract][Full Text] [Related]
6. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation.
Baumann BC; Baumann JC; Christodouleas JP; Soffen E
Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422
[TBL] [Abstract][Full Text] [Related]
7. Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes.
Zelefsky MJ; Gomez DR; Polkinghorn WR; Pei X; Kollmeier M
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):529-33. PubMed ID: 23523323
[TBL] [Abstract][Full Text] [Related]
8. Nadir PSA is a strong predictor of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radiotherapy and androgen deprivation.
Geara FB; Bulbul M; Khauli RB; Andraos TY; Abboud M; Al Mousa A; Sarhan N; Salem A; Ghatasheh H; Alnsour A; Ayoub Z; Gheida IA; Charafeddine M; Shahait M; Shamseddine A; Gheida RA; Khader J
Radiat Oncol; 2017 Sep; 12(1):149. PubMed ID: 28882187
[TBL] [Abstract][Full Text] [Related]
9. Effects of interruptions of external beam radiation therapy on outcomes in patients with prostate cancer.
Dong Y; Zaorsky NG; Li T; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MA; Horwitz EM
J Med Imaging Radiat Oncol; 2018 Feb; 62(1):116-121. PubMed ID: 29030906
[TBL] [Abstract][Full Text] [Related]
10. Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?
Andrews SF; Horwitz EM; Feigenberg SJ; Eisenberg DF; Hanlon AL; Uzzo RG; Pollack A
Cancer; 2005 Jul; 104(2):299-304. PubMed ID: 15954083
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation.
Nguyen QN; Levy LB; Lee AK; Choi SS; Frank SJ; Pugh TJ; McGuire S; Hoffman K; Kuban DA
Cancer; 2013 Sep; 119(18):3265-71. PubMed ID: 23798338
[TBL] [Abstract][Full Text] [Related]
12. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?
Castle KO; Hoffman KE; Levy LB; Lee AK; Choi S; Nguyen QN; Frank SJ; Pugh TJ; McGuire SE; Kuban DA
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):693-9. PubMed ID: 22836052
[TBL] [Abstract][Full Text] [Related]
13. Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality.
Naik M; Reddy CA; Stephans KL; Ciezki JP; Garcia J; Grivas P; Stephenson AJ; Klein EA; Tendulkar RD
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):617-23. PubMed ID: 27681757
[TBL] [Abstract][Full Text] [Related]
14. High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes.
Edelman S; Liauw SL; Rossi PJ; Cooper S; Jani AB
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1473-9. PubMed ID: 22245201
[TBL] [Abstract][Full Text] [Related]
15. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.
Shilkrut M; Merrick GS; McLaughlin PW; Stenmark MH; Abu-Isa E; Vance SM; Sandler HM; Feng FY; Hamstra DA
Cancer; 2013 Feb; 119(3):681-90. PubMed ID: 22893254
[TBL] [Abstract][Full Text] [Related]
16. Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer.
Khor R; Duchesne G; Tai KH; Foroudi F; Chander S; Van Dyk S; Garth M; Williams S
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):679-85. PubMed ID: 22954770
[TBL] [Abstract][Full Text] [Related]
17. Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy.
de Crevoisier R; Slimane K; Messai T; Wibault P; Eschwege F; Bossi A; Koscielny S; Bridier A; Massard C; Fizazi K
Ann Oncol; 2010 Apr; 21(4):808-814. PubMed ID: 19825885
[TBL] [Abstract][Full Text] [Related]
18. Intensity-modulated radiation therapy for intermediate-risk prostate cancer: does ADT still have an impact in the dose-escalated external beam radiation therapy era?
Soyano T; Kozuka T; Kashihara K; Murakami Y; Yonese J; Sasamura K; Shimoyachi N; Kashihara T; Yoshioka Y; Oguchi M
Jpn J Clin Oncol; 2023 Jun; 53(6):514-521. PubMed ID: 36946312
[TBL] [Abstract][Full Text] [Related]
19. Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
Amit U; Lawrence YR; Weiss I; Symon Z
Radiat Oncol; 2019 Jun; 14(1):99. PubMed ID: 31182119
[TBL] [Abstract][Full Text] [Related]
20. Long-term biochemical progression-free survival following brachytherapy for prostate cancer: Further insight into the role of short-term androgen deprivation and intermediate risk group subclassification.
Matzkin H; Chen J; Agai R; Ziv-Baran T; Mabjeesh NJ
PLoS One; 2019; 14(4):e0215582. PubMed ID: 31002732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
